Spoelstra E C, Westerhoff H V, Pinedo H M, Dekker H, Lankelma J
Department of Medical Oncology, Free University Hospital, Amsterdam, The Netherlands.
Eur J Biochem. 1994 Apr 1;221(1):363-73. doi: 10.1111/j.1432-1033.1994.tb18748.x.
We examined P-glycoprotein-mediated verapamil transport, using two drug-sensitive and multi-drug resistant cell-line couples, i.e. A2780, 2780AD and SW-1573, SW-1573/1R500. The interaction of 3H-labeled verapamil with cells was measured using a flow-through system. The verapamil-containing medium was pumped over the cells and monitored on-line for radioactivity. In the P-glycoprotein-expressing cells, verapamil accumulation was increased by vinblastine and some known multidrug resistant (MDR) modifiers. Subsequent removal of these modifiers caused release of verapamil into the medium against a verapamil concentration gradient. In this manner, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein. Using the flow-through system, we also exposed the cells to flowing culture medium containing daunorubicin, and measured the inhibition of daunorubicin efflux by verapamil. We found that, although the active efflux of daunorubicin was maximally blocked by verapamil short-term, longer-term active efflux of daunorubicin resumed. At a daunorubicin concentration in the flowing medium of 5 microM, increasing the verapamil concentration resulted in the same short-term effects, but in a significantly longer period of a maximal inhibition of daunorubicin efflux from the cells. At a daunorubicin concentration of 20 microM, increasing the verapamil concentration affected neither the short-term nor the long-term effects. These and other observations are in agreement with a model in which daunorubicin and verapamil are non-competing substrates for P-glycoprotein. In conclusion, we obtained evidence that verapamil is actively transported by the MDR-related P-glycoprotein and that verapamil and daunorubicin are non-competing substrates for P-glycoprotein. Consequently, the effectiveness of verapamil as an MDR antagonist may be compromised because it is extruded by P-glycoprotein.
我们使用两对药物敏感和多药耐药细胞系,即A2780、2780AD以及SW - 1573、SW - 1573/1R500,研究了P - 糖蛋白介导的维拉帕米转运。使用流通系统测量3H标记的维拉帕米与细胞的相互作用。含维拉帕米的培养基被泵送至细胞上方,并在线监测放射性。在表达P - 糖蛋白的细胞中,长春碱和一些已知的多药耐药(MDR)调节剂可增加维拉帕米的蓄积。随后去除这些调节剂会导致维拉帕米逆浓度梯度释放到培养基中。通过这种方式,我们获得了证据表明维拉帕米由MDR相关的P - 糖蛋白主动转运。使用流通系统,我们还将细胞暴露于含柔红霉素的流动培养基中,并测量维拉帕米对柔红霉素外排的抑制作用。我们发现,尽管维拉帕米可在短期内最大程度地阻断柔红霉素的主动外排,但柔红霉素的长期主动外排会恢复。在流动培养基中柔红霉素浓度为5 microM时,增加维拉帕米浓度会产生相同的短期效应,但对柔红霉素从细胞中外排的最大抑制期会显著延长。在柔红霉素浓度为20 microM时,则增加维拉帕米浓度对短期和长期效应均无影响。这些以及其他观察结果与一个模型相符,即柔红霉素和维拉帕米是P - 糖蛋白的非竞争性底物。总之,我们获得的证据表明维拉帕米由MDR相关的P - 糖蛋白主动转运,且维拉帕米和柔红霉素是P - 糖蛋白的非竞争性底物。因此,维拉帕米作为MDR拮抗剂的有效性可能会受到影响,因为它会被P - 糖蛋白排出。